Janus Henderson Group PLC trimmed its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 26.8% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,870,810 shares of the biotechnology company’s stock after selling 2,150,540 shares during the period. Janus Henderson Group PLC owned approximately 0.08% of Heron Therapeutics worth $228,081,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in shares of Heron Therapeutics during the first quarter worth $117,000. SG Americas Securities LLC purchased a new stake in shares of Heron Therapeutics during the first quarter worth $183,000. NewSquare Capital LLC purchased a new stake in shares of Heron Therapeutics during the second quarter worth $211,000. Credit Agricole S A purchased a new stake in shares of Heron Therapeutics during the first quarter worth $240,000. Finally, Aperio Group LLC purchased a new stake in shares of Heron Therapeutics during the first quarter worth $272,000.

A number of analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, August 8th. ValuEngine lowered Heron Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Wednesday, July 18th. Oppenheimer increased their target price on Heron Therapeutics from $34.00 to $50.00 and gave the company an “outperform” rating in a report on Friday, June 22nd. Finally, Leerink Swann increased their target price on Heron Therapeutics to $46.00 and gave the company an “outperform” rating in a report on Friday, June 22nd. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $50.09.

In other Heron Therapeutics news, VP Kimberly Manhard sold 6,000 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $37.53, for a total transaction of $225,180.00. Following the transaction, the vice president now owns 6,000 shares of the company’s stock, valued at $225,180. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Barry D. Quart sold 50,000 shares of the firm’s stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $39.05, for a total value of $1,952,500.00. Following the transaction, the chief executive officer now directly owns 69,600 shares in the company, valued at approximately $2,717,880. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 440,469 shares of company stock worth $17,218,958. Corporate insiders own 16.20% of the company’s stock.

NASDAQ:HRTX opened at $38.60 on Friday. The firm has a market capitalization of $2.99 billion, a P/E ratio of 10.58 and a beta of 1.56. Heron Therapeutics Inc has a 12 month low of $14.40 and a 12 month high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative return on equity of 112.35% and a negative net margin of 411.41%. Heron Therapeutics’s revenue for the quarter was up 103.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.80) earnings per share. equities analysts expect that Heron Therapeutics Inc will post -2.22 EPS for the current fiscal year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Further Reading: Earnings Per Share (EPS) Explained

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.